Results 221 to 230 of about 72,887 (326)

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel

Cancer, Volume 132, Issue 4, 15 February 2026.
Abstract Background The expansion of treatment options for prostate cancer (PC) has improved disease‐specific and overall survival outcomes but has also raised questions about the optimal level of treatment needed for patients based on their individual prognosis and accounting for potential toxicity, incorporating quality of life considerations ...
Rana R. McKay, Benjamin L. Maughan, Alicia K. Morgans, Neal D. Shore, Evan Y. Yu, Ravi A. Madan, Jacob E. Berchuck, Bradley C. Carthon, Steven E. Finkelstein, Leonard Gomella, Michael A. Gorin, Andrew W. Hahn, Stacy Loeb, Vivek K. Narayan, Daniel P. Petrylak, Charles J. Ryan, Karine Tawagi, Phuoc T. Tran, Tanya Dorff   +18 more
wiley   +1 more source

Supplementary Data from Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation <i>In vivo</i>?

, 2023
Majid Ali, Brian A. Telfer, Cian M. McCrudden, Martin O’Rourke, Huw D. Thomas, Marzieh Kamjoo, Suzanne Kyle, Tracy Robson, Chris Shaw, David G. Hirst, Nicola J. Curtin, Kaye J. Williams   +11 more
openalex   +1 more source

Clinical Outcomes of Poly(ADP-Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea. [PDF]

Curr Oncol
Ha HI, Yoon HJ, Song C, Kim ET, Suh DS, Kim KH, Na YJ, Song YJ.   +7 more
europepmc   +1 more source

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic <i>BRCA1</i>/<i>2</i>, Germline <i>PALB2</i>, or Homologous Recombination Deficiency Signature. [PDF]

JCO Precis Oncol, 2023
Batalini F, Madison RW, Sokol ES, Jin DX, Chen KT, Decker B, Pavlick DC, Frampton GM, Wulf GM, Garber JE, Oxnard G, Schrock AB, Tung NM.   +12 more
europepmc   +1 more source

The role of cytokines in ovarian cancer drug resistance

International Journal of Cancer, Volume 158, Issue 4, Page 821-834, 15 February 2026.
Abstract Ovarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. While significant advances have been made in treating various types of cancer, progress in ovarian cancer treatment over the past 20 years has been minimal, and the treatment course of ovarian cancer is not linear. Although many patients
Lu Wang, Yunxia Zang, Rebeka Dejenie, Junyuan Bing, Shixia Dong, Yanfei Zhang, Yi Zhu, Jingjing Li   +7 more
wiley   +1 more source

Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis. [PDF]

Technol Cancer Res Treat
Duan Q, Feng Y, Cao L, Hu L, Wang J, Sun F, Meng Q, Zhou M, Yu J, Gao H.   +9 more
europepmc   +1 more source

Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors. [PDF]

JCO Precis Oncol, 2022
Price MJ, Vashistha V, Winski D, Kelley MJ, Bitting RL, Montgomery B.   +5 more
europepmc   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, Volume 16, Issue 2, Page 432-446, February 2026.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

PCN207 COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS OR CHEMOTHERAPY IN GBRCA-MUTATED, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC): A US AND GERMAN HEALTHCARE PERSPECTIVE [PDF]

, 2019
Charles McCrea, David W. Macdonald, Robert Hettle, Kimmie McLaurin, A. Specht, Chantal Merens, T. Wynne   +6 more
openalex   +1 more source

Therapy-related myeloid neoplasms in Korean patients with ovarian or primary peritoneal cancer treated with poly(ADP-ribose) polymerase inhibitors. [PDF]

Transl Cancer Res
Jang YJ, Kim H, Ryu SY, Kim MH, Kim BJ, Jung HJ, Kang J, Yang SH, Na II, Lee HR, Kang HJ.   +10 more
europepmc   +1 more source